We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genome Analysis Toolkit Developed for Next-Generation Sequencing

By LabMedica International staff writers
Posted on 31 Oct 2012
A new genome analysis toolkit (GATK) provides an open-source computational engine enabling the development of analysis tools for next-generation sequencing. More...
Upon this engine, scientists have constructed a wide series of analysis tools to process data from any next-generation sequencing platform, and to identify changes in the sequences that may be associated with disease.

The Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University (Boston, MA, USA) has chosen Appistry, Inc. (St. Louis, Mo, USA) to distribute the toolkit to users at for-profit companies one of the most widely used software for data processing and variant calling of next-generation sequencing data, and to provide those users with commercial-grade customer support.

First developed and introduced by the Broad Institute in 2009, the GATK user base has grown to include thousands of biomedical researchers, bioinformatics professionals, and clinicians from a wide-range of both nonprofit as well as for-profit organizations. The GATK has been used on initiatives ranging from the 1000 Genomes Project to the National Institutes of Health’s (NIH; Bethesda, MD, USA) Cancer Genome Atlas, and by many sequencing centers and leading researchers to conduct population studies and explore the genetic origins of disease.

“Genetic research is changing the face of modern healthcare, and tools like the GATK have been essential in making the reams of data coming off of sequencers actionable,” said Appistry chief executive officer Kevin Haar. “We are honored to have been chosen to help the Broad Institute bring GATK 2.0, with customer support, to for-profit users and ensure that it remains an important source of insight in deciphering the genetic code and better managing and treating human disease.”

The GATK framework supports a wide variety of tools, with a primary focus on variant discovery and genotyping as well as strong emphasis on data quality assurance. Its architecture, powerful processing engine, and high-performance, scalable computing capabilities enable it to work on projects of any size. GATK 2.0 brings considerable enhancement over earlier releases of the toolkit, including newer and more sophisticated tools for error modeling, data compression, and variant calling.

GATK 2.0 will continue to be freely available to non-profit users under an academic, nonprofit research license agreement. Appistry will make the toolkit available to users at for-profit companies under a separate license agreement with a subscription fee that will cover commercial-grade support for installation, configuration, and documentation as well as long-term support for each commercial release. GATK 1.0, now called GATK-lite, will remain free for all users.

“We have been thrilled that the GATK has proven useful to a diverse group of users. However, as an academic institution, we don’t have the resources to offer the level of support that many for-profit users of the GATK want and need,” said David Altshuler, deputy director of the Broad Institute. “By partnering with Appistry, we are able to continue to provide the toolkit for free to nonprofit users, and to continue to extend its capabilities, while also ensuring the kind of support that users at for-profit companies have been looking for.”

Appistry combines high performance computing and analytics to provide the throughput and scale required for diverse applications--from discovering new medical therapies to delivering overnight packages, decoding military satellite images, or gaining insights from financial transactions.

The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute’s goal is to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, techniques, and data openly to the entire scientific community.

Related Links:
Broad Institute of the Massachusetts Institute of Technology and Harvard University
Appistry




New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.